Dermatologists oppose OTC mometasone for topical use

Dermatologists and the AMA are opposing a TGA proposal to down-schedule topical mometasone products  (0.1% or less in packs of 15g or less) from a Schedule 4 to a Schedule 3 drug. In a submission to the TGA Advisory Committee on Medicines Scheduling (ACMS), the AMA said dermatologist and GP members were unanimous that the ...

Already a member?

Login to keep reading.

© 2022 the limbic